Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 25Salivary Gland Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Prostatic Diseases 2Non-metastatic Castration-resistant Prostate Cancer 2Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Male Urogenital Diseases 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Urogenital Neoplasms 1Urogenital Diseases 1Sleep Initiation and Maintenance Disorders 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Neoplasms by Site 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Neoplasms 1High-Risk Localized Prostate Cancer 1Granulosa cell tumor of the ovary 1Genital Diseases, Male 1Fatigue 1Depression 1Advanced Solid Tumor 1Adenocarcinoma 1

Interventions

Prednisone 5Docetaxel 4niraparib 2enzalutamide 2darolutamide 2Pluvicto 2Abiraterone Acetate 2olaparib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1abiraterone 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1JNJ-64619178 1JNJ-64264681 1Dexamethasone 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × darolutamide × 90 days × Clear all
NCT05997615 2026-04-20

AMX-500

Vir Biotechnology, Inc.

Phase 1 Recruiting
390 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡